RxDoctor Payments Data

Deborah Leverette

Psychiatry · Columbia, SCNPI 1073619847

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,350 of the $11,144 with a category attached, or 66.0%. AbbVie accounts for 74.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $8,378 and has fallen 95.0% since, to $417 in 2025. Among psychiatry clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,144in general payments, 2019–2025

Across 197 payments — averaging $56.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Neurocrine Biosciences, Inc.$814
  • Jazz Pharmaceuticals Inc.$243
  • Alkermes, Inc.$230
  • Otsuka America Pharmaceutical, Inc.$209
  • Ironshore Pharmaceuticals Inc.$202
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$7,35066%
  • Travel & lodging$2292%
  • Food & beverage$3,53532%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,144 in reported general payments places this provider in the 90th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$127,554
VraylarCariprazine Hcl54$99,830
TrintellixVortioxetine Hydrobromide20$20,953
RexultiBrexpiprazole12$17,404
VyvanseLisdexamfetamine Dimesylate21$7,854
FetzimaLevomilnacipran Hcl13$7,442
Lurasidone Hcl34$5,938
Desvenlafaxine Succinate ErDesvenlafaxine Succinate29$4,905
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine112$3,004
Ziprasidone Hcl24$2,672
Bupropion XlBupropion Hcl61$2,351
Eszopiclone27$1,969
Vilazodone Hcl12$1,561
Lamotrigine48$1,379
Clonazepam138$1,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$814$127,55416 claims
AbbVieVraylar, Fetzima$8,259$107,27267 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$156$28,80741 claims
Otsuka America Pharmaceutical, Inc.Rexulti$209$17,40412 claims
Almatica Pharma LLCSertraline Hcl$48$44114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →